ChemicalBook > CAS DataBase List > Edobacomab
Edobacomab
- Product Name
- Edobacomab
- CAS No.
- 141410-98-2
- Chemical Name
- Edobacomab
- Synonyms
- Edobacomab;Research Grade Edobacomab;Research Grade Edobacomab (DXX02202);Immunoglobulin M (mouse monoclonal XMMEN-0E5 anti-endotoxin), disulfide with mouse monoclonal XMMEN-0E5 light chain, pentameric dimer;Immunoglobulin m (mouse monoclonal xmmen-oe5 anti-endotoxin), disulfide with mouse monoclonal xmmen-oe5 light chain, pentameric dimer
- CBNumber
- CB21118456
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Edobacomab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Edobacomab Suppliers
- Tel
- 010-56205725
- Fax
- 010-65763397
- waley188@sohu.com
- Country
- China
- ProdList
- 12335
- Advantage
- 58
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
- Tel
- 51288865780
- sales@biosynth.com
- Country
- China
- ProdList
- 6051
- Advantage
- 58
141410-98-2, EdobacomabRelated Search:
Anselamimab
Immunoglobulin G1,anti-(human NCA-90 granulocyte cell antigen) (mouse monoclonal IMMU-MN3 g1-chain), disulfide with mousemonoclonal IMMU-MN3 k-chain, dimer (9CI)
Vopratelimab
Plamotamab
reslizumab
Lymphocide
Siplizumab
Vibecotamab
Rontalizumab
Tesnatilimab